INFO & CONTACTS:  +39 02 2390 1

Omission of local therapies in women patients with HER2-positive or triple-negative breast cancer. A two arm, phase 2, non-inferiority trial for surveillance in maximum responders to neoadjuvant systemic therapy.

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Gennaro Massimiliano

Main Facility: Chirurgia Senologica

Drug: Not Applicable

Pathologies: Breast cancer (TNBC)

HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%. This gave rise to doubts about the usefulness of traditional local treatments for such responders. Omission of surgery after VABB (vacuum assisted breast biopsy) as well omission of radiotherapy after conservative surgery would now seem to be reasonable alternatives to standard care for higly selected patients, in whom systemic treatments have provided the maximum response.

Last update: 12/05/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe